PS3 10% 2-1
2-2
2-3
2 23 2-4
1 2 3 4 2-5
2.3.1 1 24 812 2-6
5 5% : (CVC) 5 2-7
CTZ 24 24 2-8
2.3.2 23 5HT3 12 2-9
2.3.3 12 12 23 710 13 5-FU 2-10
2.3.4 24 10 20 5-FU 2-11
2-12
(CTZ) 5HT3 H1 Achm (CTZ) D2 5HT3 NK1 H1 Achm 5HT2,, Achm D2 5HT3 Oxford Textbook of Palliative Medicine 3rd 2004 12 2-13
( 24 5HT3 5HT3 ASCO 24 2 24 24 5HT3 2-14
ASCO 24 24 50 2 < ASCO 2-15
ASCO http://www.cancerit.jp/cancer_references/archive/no228_ascoguide2006_nau seavomiting.html 2-16
1496 BRM // 23 2-17
CHOP 6 2-18
2-19
2.6 1 9L 100200ml 9L) 2L 1L 2L 2L 1L 1L 9L) 35L 24L 12L 100200mL O-157 5-FUTS-1UFT 5-FU 10 2 2-20
10 2 SN-38 2-21
8 7 120 (PS) 2.7.1 12 710 500/mm 3 100/mm 3 38 G-CSF 2-22
2.7.2 20,000/mm 3 2-23
2.7.3 2-24
12 710 34 2-25
3540% QOL 714 3 7 47 3 7 4-7 http://cancerinfo.tri-kobe.org 2-26
5-FU 5-FU E 30 2-27
2-28
23 36 2 2-29
2.10.1 5-FU 2-30
QOL 2.10.2 (FGFR) PLWC(people living with cancer) erlotinib ( Tarceva) cetuximab ( Erbitux) EGFR http://www.plwc.org/portal/site/plwc/menuitem.169f5d85214941ccfd748f68 ee37a01d/?vgnextoid=81dd2daf1034b010vgnvcm100000ed730ad1rcrd EGFR EGFR 45100 2-31
SPF 30 1/30 2 1 2-32
15 24 T erlotinib ( Tarceva) cetuximab ( Erbitux) URL 2-33
QOL QOL 2-34
2-35
5-FUUFTTS-1 5-FU 5-FUUFTTS-1 2-36
2-37
95 5% 35008000/mm 3 10 1500018000/mm 3 10 15000 18000/mm 3 4000/mm 3 30000/mm 3 95 CEA CEA 95 2-38
2-39
QOL QOL QOL QOL QOL QOL QOL QOL QOL 30 EORTC 30 (C30) QOL QLQ EORTC-QLQ-C30 FACT-G 2 1 QOL QOL QOL QOL 2030 2-40
QOL QOL QOL QOL QOL QOL QOL QOL QOL EORTC-QLQ-C30 EORTC-QLC-C30 QOL QOL QOL QOL QOL 2-41